Jin Rong Jie·2025-08-25 02:10Core Viewpoint - Rongchang Biologics (09995) reported a strong performance in its mid-year results for 2025, showing significant growth in revenue and a reduction in net loss, driven by the sales of its commercialized products [1] Financial Performance - The company reported product sales and R&D service revenue of 1.092 billion yuan, representing a year-on-year increase of 47.6% [1] - R&D expenses decreased by 19.7% to 647 million yuan [1] - The net loss was approximately 450 million yuan, a reduction of 42.4% year-on-year [1] - Earnings per share showed a loss of 0.83 yuan [1] Product Performance - The increase in revenue was primarily attributed to the strong sales growth of the company's autoimmune commercial product, Taitasip, and the oncology commercial product, Vidisizumab [1]